US EditionTreating primary bone cancer: The potential of listeria-based bioengineered bacterial immunotherapy
Summary by Pharmaphorum
1 Articles
1 Articles
All
Left
Center
1
Right
Treating primary bone cancer: The potential of listeria-based bioengineered bacterial immunotherapy
In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Paul Romness, president and CEO of OS Therapies, a company focused on the identification, development, and commercialisation of treatments for osteosarcoma (OS) and other solid tumours.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium